Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio

By LabMedica International staff writers
Posted on 13 Feb 2025
Print article
Image: ABL and affiliates will start production and commercialization of FTD’s new UltraGene products based on PCR tests (Photo courtesy of Siemens)
Image: ABL and affiliates will start production and commercialization of FTD’s new UltraGene products based on PCR tests (Photo courtesy of Siemens)

Advanced Biological Laboratories (ABL, Luxembourg Ville, Luxembourg) has signed a licensing and transfer agreement with Siemens Healthineers (Forchheim, Germany) for the know-how and IP rights from Fast Track Diagnostics Luxembourg (FTD).

FTD was engaged in developing, manufacturing, and selling in-vitro diagnostic and research using only molecular testing products. As the owner of FTD, Siemens has licensed and transferred the know-how and IP rights to ABL and its affiliates (ABL Group) related to the design and manufacturing of certain former FTD products. Based on this Know-How License and Transfer Agreement (Agreement), the ABL group intends to manufacture and commercialize its testing products equivalent to the former FTD products. The licensed know-how is related to real-time Polymerase Chain Reaction (PCR) tests, allowing for both singleplex and syndromic testing, to target conditions such as respiratory infections, gastroenteritis, meningitis, hepatitis, infections of the immunosuppressed, tropical diseases, sexually transmitted diseases, and early childhood diseases, and detect over 100 viruses, bacteria, parasites, and fungi.

Unlike a clinical examination alone, it can distinguish between viral, bacterial, or other infections in one test. By integrating new PCR tests based on FTD know-how and IP rights to its molecular diagnostics portfolio, ABL Group is further investing in precision medicine and better patient experience through solutions that eliminate the need for repeat diagnostic testing, reducing time and improving patient outcomes. The Agreement expands the ABL Group molecular diagnostics portfolio with a potential of up to 38 products to be manufactured within the ABL UltraGene family. ABL intends to develop a combined strategy of reflex testing from these new products and the DeepChek products for genotyping sequencing. This will further expand ABL’s footprint in infectious diseases by being a global supplier of standalone software, detection tests, and genotyping by sequencing tests. The expanded ABL portfolio, tests, and syndromic panels, can help transform care delivery for its customers with a comprehensive solution for molecular testing of infectious diseases. In addition, ABL's platform-agnostic menu allows ABL Group to effectively serve a broader customer base.

"By integrating the high-quality of the know-how developed by Fast Track Diagnostics into our own cutting-edge molecular diagnostics portfolio, ABL continues to strengthen and expand its presence in the field of molecular testing and precision medicine," said Dr. Chalom B. Sayada, CEO and Founder, Advanced Biological Laboratories. "It means great things for all of our customers globally and delivers better outcomes for their patients."

"We are excited to manufacture our new ABL UltraGene products using FTD’s know-how and IP rights and to integrate them into our compliance plan to the European regulation for in-vitro diagnostics medical devices (2017/746, IVDR)," added Ronan Boulmé, GRC Director for the ABL Group.

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.